Strategic-collaboration-with-EnaraBio Strategic-collaboration-with-EnaraBio Boehringer Ingelheim and Enara Bio enter strategic collaboration and licensing agreement to discover novel shared antigens for cancer immunotherapies.
Acquisition expands research in cancer immunology Acquisition expands research in cancer immunology Boehringer Ingelheim acquires Abexxa to develop novel cancer therapies by leveraging Abexxa’s unique technology and breakthrough antibody-based drugs.
Second cancer immunotherapy partnership with 3T Bio Second cancer immunotherapy partnership with 3T Bio Second cancer immunotherapy partnership with 3T Bio
License deal with A*STAR to develop cancer antibodies License deal with A*STAR to develop cancer antibodies License deal with A*STAR to develop cancer antibodies
Taking Cancer on Through Flavour Taking Cancer on Through Flavour Recipes developed specifically for people living with cancer. Contributions from a chef, a dietitian, and a cancer survivor.
“My ultimate goal is to cure cancer” “My ultimate goal is to cure cancer” Norbert Kraut, our Global Head of Cancer Research, shares how we are advancing science to bring new treatment options for people living with cancer.
Oncology and Cancer Immunology Research Oncology and Cancer Immunology Research Find out more about our research and development in oncology and cancer immunology.
Experiences of living with cancer Experiences of living with cancer We know from speaking with people living with cancer and their loved ones, that it’s often the small moments that can be the most significant.
T-cell engagers: Reawakening T-cells to fight cancer T-cell engagers: Reawakening T-cells to fight cancer Learn how we are taking cancer on through our approach to immuno-oncology and our T-cell engagers plarform
The power of patient advocacy in cancer care The power of patient advocacy in cancer care Larry, a retired US Navy veteran, and Jeff, UICC President, have more in common than a cancer diagnosis: they share a passion for patient empowerment.
Why cancer care is personal for us Why cancer care is personal for us At Boehringer Ingelheim, we have made a generational commitment to transforming cancer care, with the ultimate goal of curing a range of cancers.
Accelerating new cancer medicines in partnership with CBmed Accelerating new cancer medicines in partnership with CBmed Boehringer Ingelheim and CBmed join forces to translate novel cancer therapy approaches faster into new medicines for patients
Larry’s Story: Advocating for people with lung cancer Larry’s Story: Advocating for people with lung cancer In 2013, Larry was diagnosed with non-small cell lung cancer. Learn how his diagnosis led him on a journey of patient advocacy for others with cancer.
Veterinary oncology - cancer treatment Veterinary oncology - cancer treatment Our R&D team's efforts toward finding new cancer treatments for pets
Boehringer Ingelheim invests in precision cancer treatments Boehringer Ingelheim invests in precision cancer treatments Boehringer Ingelheim Venture Fund invests in Synthetica as part of its commitment to advancing innovative, next-generation cancer therapies
New cancer therapeutics collaboration with 3T Bio New cancer therapeutics collaboration with 3T Bio Boehringer Ingelheim and 3T Biosciences collaborate to discover and develop next-generation cancer therapies to address high unmet patient needs
Breaking prejudice in lung cancer Breaking prejudice in lung cancer At Boehringer Ingelheim, addressing patient needs and fighting stigma in lung cancer care are two focus topics of the patient engagement team in oncology.
Targeting HER2 in cancer: The story of zongertinib Targeting HER2 in cancer: The story of zongertinib We discovered zongertinib, an HER2 tyrosine kinase inhibitor, being developed as a potential oral treatment for people with HER2-mutated NSCLC
Facing lung cancer Facing lung cancer Keith and Heather talk about their experiences of facing lung cancer as a family and finding purpose after treatment.
New cancer research building: Boosting innovation in oncology New cancer research building: Boosting innovation in oncology With our new cancer research building in Vienna, we’ll advance our oncology pipeline and strengthen our commitment to innovation and collaboration.
SIRPα Cancer Immunology Research SIRPα Cancer Immunology Research Boehringer Ingelheim scientists are investigating a new target in the innate immune system - signal-regulating protein alpha or SIRPα.